CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
GRF6019drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03520998
NCT03520998Phase 2Completed
CompareCT.gov

A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease

Alkahest, Inc.·interventional·Posted May 11, 2018·Updated Jan 29, 2021

In Brief

A Phase 2 clinical trial evaluating GRF6019 for Alzheimer Disease and Mild to Moderate Alzheimer Disease. Completed, enrolled 47 participants across 10 sites.

Detailed Summary

This study is evaluating the safety, tolerability, and feasibility of GRF6019, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with mild to moderate Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Mild to Moderate Alzheimer Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 11, 2018
Enrollment StartApr 16, 2018
Primary CompletionMay 24, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.1 years ago

Interventions

GRF6019drug

GRF6019 for IV infusion